New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Konica Minolta has agreed to acquire Ambry Genetics for up to $1 billion, the companies said on July 5, 2017, in a deal the buyer envisions as the first step in its strategy of developing a ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics defeated an appeal by Myriad Genetics to block competing DNA-based tests to determine hereditary risk for breast and ovarian cancer after a ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Just weeks after it lost at the high court, Myriad filed new lawsuits against the first two competitors who began offering BRCA gene testing, Ambry Genetics and Gene by Gene. Despite its Supreme ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...